Vanderbilt University Medical Center researchers announced in June 2026 that ifetroban, a drug developed to protect the heart and blood vessels, may also lower the risk of cancer metastasis. Patients on ifetroban in a small early trial were far less likely to develop distant spread than those on placebo.
The Phase 2a study, run with Cumberland Pharmaceuticals, enrolled 29 patients with breast, lung, pancreatic, soft tissue, bladder and renal cancers considered at high risk of early recurrence. Seventeen percent of those on ifetroban developed a distant metastatic recurrence, compared with 50 percent in the placebo group. Three patients in the placebo group died of metastatic disease. None did in the treatment arm.
The trial was small. The difference in recurrence did not reach the conventional threshold for statistical significance (p=0.091), though the difference in metastasis-related deaths did (p=0.037). Larger studies will be needed to confirm any benefit.
Where a heart drug meets cancer biology
Ifetroban is a thromboxane A2 receptor antagonist. It blocks the signal that activates platelets, the tiny blood cells that clot at a wound. In cardiovascular disease, that platelet-clumping is what drives clots and heart attacks.
Also read: Researchers raise concerns over paracetamol in pregnancy
In cancer, tumor cells appear to hijack the same platelets as an escort, using them to slip through blood vessel walls, invade distant organs and hide from the immune system. Blocking the receptor is meant to strip that cover away.
The idea to test the drug in cancer came from Vanderbilt's BioVU, a DNA biobank linked to de-identified health records. A scan of the biobank tied a common variant in the thromboxane receptor gene to a higher risk of metastatic disease across multiple cancer types.
Preclinical work backed the theory. In triple-negative breast cancer models, blocking the thromboxane receptor cut both lung and liver metastases without slowing growth of the primary tumor itself.
Why the cardiac safety record matters
Ifetroban already has a long safety record from cardiovascular research, which is one reason it could move quickly into larger cancer trials. In the Phase 2a study, treatment-related side effects were similar between the placebo and ifetroban groups, with no serious adverse events tied to the study drug. Participants took a daily oral pill for 12 months and were then followed for another 12 months.
Also read: How to protect your hands from early signs of aging
"A therapeutic intervention aimed at metastasis prevention for cancer patients with high risk of recurrence that is given during the period of 'watchful waiting' could be groundbreaking if proven beneficial in larger scale investigations," said Ben Ho Park, MD, PhD, of Vanderbilt-Ingram Cancer Center.
Metastasis, the spread of cancer from where it started to a distant organ, is what makes most solid tumors lethal. Anything that slows or blocks that step could change how doctors treat cancer patients in the window after surgery, when doctors and patients are watching for signs of return.
Ifetroban is not an approved cancer treatment. The Phase 2a study is a pilot, designed to test safety and look for early signals, and any use of the drug in cancer patients today would only happen inside a clinical trial. Patients with a cancer diagnosis who are interested in trial options should raise them with their oncologist. Larger studies are needed before regulators can decide whether ifetroban belongs in cancer care.
Also read: The daily amount of cranberry extract that may actually protect your bladder from UTIs
This article is made and published by Mie Hermansen, who may have used AI in the preparation.